Table 1.

Summary of clinical data, positron emission tomography/computed tomography findings and follow-up

Patient	Age (years)	Sex	Presentation	Serum prolactin (ng/mL)	MRI findings	18F-fallypride tumour uptake (percentage relative to the putamen)	18F-fallypride tumour uptake (relative to the cerebellum)	11C-methionine (HS/normal uptake in the cerebellum)	Follow-up
1	69	Male	Prolactinoma	1006	Macroprolactinoma 26 × 20 × 20 mm	31	3,8	1,1	Treatment with cabergoline. Reduction of serum prolactin to 16.0 ng/mL, with no change in tumor size
2	63	Female	NFPA	35.3	Macroadenoma 44 × 25 × 23 mm. Extra-pituitary extension	120	15,4	4,1	The patient had previous surgery and radiotherapy. Cabergoline was initiated at 2 mg/week. The lesion remained stable on MRI
3	27	Female	Prolactinoma	470	Cystic macroprolactinoma 34 × 15 × 14 mm	30	5,6	1,4	Treatment with cabergoline. Reduction in tumor size
4	64	Male	Prolactinoma	1447	Cystic macroprolactinoma 18 × 15 × 15 mm	18	2,3	1,6	Treatment with cabergoline. Normalization of serum prolactin, with no change in tumor size on MRI
5	42	Male	Prolactinoma	356	Cystic macroprolactinoma 27 × 30 × 20 mm	70	11,5	3	Treatment with cabergoline. reduction in tumor size
6	46	Female	Prolactinoma	270	Macroprolactinoma 20 × 20 × 18 mm. Extra-pituitary extension	12	4,1	3,8	The patient underwent surgery due to a poor response to cabergoline

Clinical data, ¹⁸F-fallypride and ¹¹C-methionine uptake and follow-up. NFPA: Nonfunctioning pituitary adenoma; HS: Hotspot; MRI: Magnetic resonance imaging